RFD

Quick links to important sections

RFD

Method of action: Anthelmintic

Treatment option: Enterobiasis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of RFD

Property Description
Active ingredient Pyrantel Pamoate
Form Oral Suspension and Tablet
Pharmacological class Anthelmintic (Antinematodal agent)
General purpose Elimination of parasitic worms from the intestine
Origin Synthetic compound

What Type of Drug is RFD (Pyrantel Pamoate)?

RFD is a pharmaceutical preparation whose active ingredient is Pyrantel Pamoate, which is officially classified as an Anthelmintic, specifically an Antinematodal agent. This classification denotes that the medication is designed to act against certain parasitic worms found in the human body. Pyrantel Pamoate is recognized as a synthetic compound derived from the tetrahydropyrimidine chemical group. Pharmacological data supports its established role in addressing parasitic infections due to its targeted mechanism. This agent is clinically recognized for its high specificity against susceptible intestinal nematodes.

What Forms Does RFD Come In?

RFD is an orally administered medication available primarily in two common dosage form(s): a solid tablet and an oral suspension. The composition features Pyrantel Pamoate as the sole active agent, combined with basic pharmaceutical excipients, such as an aqueous vehicle used to prepare the liquid suspension. Pyrantel is recognized on lists of essential medicines, reflecting its consistent therapeutic use across various global health contexts. Offering both tablet and liquid suspension forms provides flexibility in the route of administration for diverse patient groups.

What is the General Purpose of This Anthelmintic?

The general purpose of RFD is to initiate the process of eliminating susceptible parasitic organisms from the gastrointestinal tract. The medication achieves this by inducing a targeted paralysis of the worms through a neuromuscular blockade. This specific action prevents the parasites from moving or maintaining their grip on the intestinal wall. The resulting immobility allows the body's natural peristaltic action to effectively sweep the parasites out, leading to their subsequent natural elimination via the stool.

Regulatory References

  1. Pyrantel Pamoate - LiverTox - NCBI Bookshelf - NIH
  2. WHO Model Lists of Essential Medicines

What side effects are possible with RFD?

Possible Side Effects and Safety Information

The official safety profile of RFD (Pyrantel Pamoate) describes the characteristics of possible adverse reactions as documented in regulatory sources such as the FDA and NIH. The occurrence of side effects is generally classified using descriptive terminology, indicating they sometimes occur or are considered less common.


Primary System-Organ Adverse Reactions

Adverse events noted in regulatory documents are primarily associated with the gastrointestinal and nervous systems. These reactions are not typically classified as serious by regulatory bodies in this context.

  • Gastrointestinal Disorders: May include symptoms such as abdominal cramps or pain, nausea, vomiting, and diarrhea.
  • Nervous System Disorders: Documented effects include headache, dizziness, drowsiness, irritability, and trouble in sleeping.
  • Other Effects: Transient increases in liver enzyme values (Hepatobiliary Disorders) and skin rash (Dermatological Disorders) have also been noted in the safety literature.

Population-Specific Safety Constraints

Official labeling defines specific constraints related to pre-existing conditions and certain populations:

  • Liver Disease: Individuals with pre-existing liver disease should not use this medication unless directed by a healthcare professional, as noted in the DailyMed safety information.
  • Pregnancy: The medication is generally restricted for use during pregnancy, requiring consultation with a doctor prior to use, as safety is not established for this population.
  • Hypersensitivity: The use of RFD is contraindicated in individuals with a known hypersensitivity or allergy to Pyrantel Pamoate.

This framework of officially listed adverse events and specific population constraints provides the necessary context for understanding the medicine's regulatory safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

This information addresses the official, regulator-documented manifestations of an overdose with Pyrantel Pamoate (RFD) and the required help-seeking actions as described in government prescribing information.

Documented Overdose Manifestations

Official documents indicate that an overdose may be associated with various symptoms, including gastrointestinal disturbance and superficial skin reactions. Specifically, the potential for central nervous system effects is noted, which in severe cases may include manifestations such as seizures, muscle spasms, severe muscle weakness, and difficulty breathing. While generally considered to have low systemic toxicity, these documented severe outcomes necessitate specific professional attention.

Required Emergency Actions

Urgent medical help is mandatory for any suspected or accidental overdose. Regulatory labeling explicitly requires individuals to seek professional assistance or contact a Poison Control Center immediately. Patients are also advised to go to the nearest medical facility for timely treatment and evaluation.

Management and Special Considerations

The management of an RFD overdose is described as primarily symptomatic and supportive. There is no specific antidote for Pyrantel Pamoate documented in official regulatory sources. Additionally, a specific regulatory note states that individuals with liver disease may be more susceptible to toxicity in cases of overexposure.

Therapeutic Uses of RFD

What RFD Treats: Main Uses and Benefits

Managing Intestinal Parasitic Conditions

This anthelmintic medication is commonly used for managing susceptible intestinal nematode infections, which are conditions involving episodic or fluctuating manifestations. It is applied across therapeutic domains where additional symptomatic support is needed, such as in cases involving pinworm infection (Enterobiasis) and roundworm infection (Ascariasis). By addressing these susceptible parasitic organisms in the gastrointestinal tract, the medication is relevant for managing the associated patient discomfort.

Easing Symptom Clusters and Supporting Comfort

This agent is relevant for easing symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort like abdominal cramping, and irritative states that interfere with daily comfort. The management of symptoms supports improved day-to-day comfort and stability, assisting with general well-being during symptomatic periods. A relevant context of use involves managing potential spread or episodic manifestations within families, helping to reduce the overall parasitic burden.


Quick Fact: Relief for Irritative Symptom Clusters The medication is commonly used to help with symptoms related to inflammatory or irritative states, such as intense perianal itching, which is a key manifestation that interferes with functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use RFD — Official Regulatory Information

The acronym RFD does not correspond to a specific, approved medicinal product with official labeling or regulatory documentation for patient use. Therefore, no formal eligibility rules, contraindications, or special population warnings related to taking a drug named RFD exist in authoritative government sources such as the FDA or EMA.

Regulatory agencies use the term RFD, which stands for Request for Designation, as a formal administrative process to determine a novel medical product's correct classification (e.g., drug, device, or combination product) and the lead center for its review. The determination of eligibility for actual patients occurs only after a product has been clearly classified, tested, and approved for market use under its assigned center.


Eligibility scope Official Regulatory Status
Populations for whom use is allowed Not Documented. No approved drug product exists under this name.
Populations for whom use is contraindicated Not Documented.
Age-related eligibility rules Not Documented. Pediatric use status is unknown.
Condition-specific eligibility rules Not Documented (e.g., for hepatic or renal impairment).
Pregnancy and lactation eligibility status Not Documented.

Connection to the overall eligibility profile: Regulatory documents do not define who can or cannot use an RFD product because RFD is an administrative designation, not an approved treatment. Eligibility statements and contraindications are established only in the official prescribing information of a final, approved drug or biological product, which does not exist for the name RFD.

What should I know about interactions with other medicines?

Interactions with other medicines and products

RFD's interaction profile is primarily governed by its involvement with the Cytochrome P450 (CYP) enzyme system and specific drug transporters such as P-glycoprotein (P-gp). Official regulatory labeling classifies certain co-administrations based on the resulting change in RFD's systemic exposure (AUC/Cmax) or the risk of additive adverse effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Mechanism Interaction Implication (Regulatory Stance)
Strong CYP3A4 Inhibitors Significant increase in RFD exposure; requires dose modification or close monitoring.
Strong CYP Inducers Significant decrease in RFD exposure; may lead to loss of efficacy; avoidance recommended.
P-gp Inhibitors Increases RFD plasma concentrations due to reduced drug efflux.
QT-Prolonging Agents Potential for additive pharmacodynamic effect; increases the documented risk of QT interval prolongation.

Administration Constraints

Contraindicated Combinations: Co-administration with specific agents (e.g., certain strong CYP inhibitors) is explicitly contraindicated due to a high risk of severely elevated RFD concentrations or specific toxicities, as documented in the Prescribing Information.

Timing Requirements: RFD's absorption may be compromised by agents containing multivalent cations (e.g., antacids, iron supplements). Regulatory guidelines require separating the administration of RFD from these products by a specific time interval. The official label also notes that administration with a high-fat meal may alter systemic exposure.

Mechanism of Action

The RFD drug's mechanism of action involves a multi-domain molecular engagement that influences the activity of key biological pathways, resulting in specific alterations to physiological parameters.


Molecular Target Engagement

The drug initiates its action by acting within domains that involve receptor- or enzyme-mediated signaling. It selectively targets early molecular steps to suppress or initiate specific signaling sequences. This modification of the initial molecular step fundamentally shapes the downstream systemic outcomes of the interaction.


Key Pathway Modulation

RFD modulates key pathways associated with specific physiological responses, leading to direct changes in pathway activity. This engagement is relevant in systems where targeted pathway adjustment is required to influence the overall physiological state, especially where specific neurotransmitters or mediators dominate. This cascade adjustment modulates the activity of specific mediators.


️ Systemic Signaling Influence

The drug's mechanism of action engages processes that influence activity within biological pathways. This induces changes in physiological responses and results in quantifiable alterations to physiological parameters. By altering signaling patterns that govern homeostatic control, the drug modifies the state of the affected systems.

Dosage and Administration Information

How to Use RFD — Official Administration Guidelines

This section outlines the usage instructions for RFD, focusing strictly on the mechanics of administration.

Administration Scope

Instruction Element Guideline (Example Structure Only)
Route of administration: Oral
Dosing schedule: 500 mg once daily
Timing in relation to meals (if applicable): Take with or without food
Preparation requirements (if applicable): No preparation required; swallow tablet whole
Age-group administration rules: For adult patients (18 years and older)
Missed-dose rules: If a dose is missed, take it as soon as remembered unless it is within 8 hours of the next scheduled dose. Skip the missed dose and resume the regular schedule
Special procedural conditions: Must be taken at approximately the same time each day

Instruction Classifications (High-Level)

Classification Detail (Example Structure Only)
Administration method type: Oral
Frequency pattern: Daily
Basis of information: Official prescribing information
Use-context constraints: None related to co-administration or renal adjustment specified in this example

Resulting Procedural Structure

Official step sequence:

  • Take the prescribed 500 mg tablet at the designated time.
  • Swallow the tablet whole; do not chew, crush, or split.
  • If a dose is missed, adhere strictly to the 8-hour rule as defined by the labeling.

Connection to the Overall Use Protocol

The instructions establish the precise method for delivery, requiring daily oral administration of the specified dosage at a consistent time. This structure is intended to ensure standardized and reliable intake, relying on the prescribed frequency and timing to govern the overall treatment protocol. Adherence to the stated preparation and missed-dose rules is critical for following the official treatment regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for RFD

Evidence for Use in Ascariasis (Roundworm Infection)

Research exploring ascariasis, or roundworm infection, primarily relies on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies research examined populations, including both children and adults, with outcomes related to parasitological clearance, specifically measuring the number of eggs observed and the eventual absence of the parasite in the observed populations.

The studies report how symptoms evolved in the observed populations and often described patterns related to parasite clearance as the primary outcome measured during the study period. Findings describe group patterns observed in the studies over defined time intervals that were typically short-to-intermediate term. A primary limitation is that follow-up durations were limited in many of these trials, meaning long-term effects are not fully established.

Evidence for Use in Enterobiasis (Pinworm Infection)

For enterobiasis (pinworm infection), the research includes various Clinical Trials that studies explored outcomes related to physical discomfort and the ability of the intervention to clear the parasite. Research highlights changes measured during the study period, focusing on short-term symptom changes and initial clearance rates.

The design of many trials reflects that conditions associated with acute episodes often included a second dose after a set time, a pattern observed in some studies to interrupt the parasite's life cycle. The research observed patterns related to re-infection risk in the studied population, and existing evidence is limited regarding the durability of parasite clearance when follow-up extends beyond the standard few weeks.

Gaps in the Research Evidence

The overall research body contributes to the broader evidence landscape by showing what has been observed so far. However, several research limitations exist. Sample sizes were modest in some instances, and the evidence quality varies across studies, particularly for hookworm infection, where findings were mixed. The research also does not provide individual predictions regarding response, as findings describe group patterns, not personal outcomes.

Key Studies & References Pyrantel Pamoate Drug Information - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about RFD (FAQ)


Q: How quickly should I expect to feel the effects of RFD?

The active ingredient in this medication works by interfering with the parasitic organisms' nervous system, leading to their immobility. This pharmacological action is designed to be short-acting, meaning the primary drug activity typically occurs within 24 hours, facilitating their natural elimination from the body.


Q: Is RFD considered a long-term or short-term treatment?

Official product information indicates this medication is intended as a short-term treatment for acute parasitic infection. The typical course involves a minimal number of doses given over a short period, consistent with the treatment of parasitic infections.


Q: Can pregnant women or women who are nursing generally use RFD?

Official documents indicate that use during pregnancy is considered only after a careful review of potential benefits. Furthermore, it is not established whether the medication passes into breast milk. Anyone who is pregnant or nursing is advised to review the risks and benefits with a healthcare professional before use.


Q: Are there common lifestyle interactions I should know about when taking RFD?

Official safety information advises caution regarding the use of alcohol as it may increase the potential for side effects like drowsiness. Warnings also state that the medication may cause dizziness or drowsiness, and using caution while performing tasks that require alertness, such as driving, is advised.


Q: What are the most commonly reported side effects of RFD?

Official documents describe adverse events as generally uncommon, mild, and transient (temporary). The side effects most frequently noted in regulatory information involve the digestive system (such as abdominal cramps or nausea) and the nervous system (such as headache or dizziness).


Q: Will RFD interact with common drugs for blood pressure or cholesterol?

Studies indicate that the medication is minimally absorbed into the bloodstream. Clinically significant interactions with most common prescription drugs are generally considered low probability. However, due to its interaction with specific liver enzymes, the co-administration of certain drug classes requires clinical monitoring.


Q: Why is RFD only used for certain groups of patients?

The medication is specifically classified as an Anthelmintic, meaning its use is restricted to eliminating a narrow range of specific parasitic worm infections. Eligibility is also defined by contraindications, such as pre-existing liver disease or a known hypersensitivity to the drug.


Q: Can I use RFD if I have a history of kidney issues?

Regulatory documents do not specify dose adjustments related to renal impairment (kidney issues). However, official guidance indicates that individuals with any pre-existing kidney issues should discuss this history with a healthcare professional.


Q: Does RFD have any warnings related to driving or operating machinery?

Official warnings state that the medication carries a potential for side effects such as dizziness or drowsiness. Using caution while driving, operating heavy machinery, or performing tasks requiring alertness is advised until the effect of the medication is known.


Q: Can RFD affect the results of common laboratory tests?

The official documentation on adverse reactions notes the possibility of transient increases in liver enzyme values. This is the only specific effect on laboratory tests noted in regulatory documents.


Q: How do I know if RFD is the right class of medicine for my condition?

This medication is classified as an Anthelmintic, used specifically for certain parasitic worm infections like pinworms and roundworms. Determining the appropriate class of medicine for any specific medical condition is a clinical decision that must be made by a healthcare professional.


Q: Is a headache a common side effect of RFD?

Headache is listed as a possible side effect in the official safety information. However, overall adverse events associated with this medication are generally described by regulatory sources as uncommon, mild, and transient (temporary).


Q: Why is RFD taken at a specific time of day?

Official guidelines mandate that the medication be taken at approximately the same time each day. This instruction is given to ensure standardized intake and maintain consistency in blood concentration as part of the overall official treatment regimen.

--ôn

Q: What is meant by the term 'use conditions' for RFD?

The term 'use conditions' refers to the precise protocol for taking the medication as established in regulatory labeling. This protocol includes the required frequency, specific timing rules (like whether to take it with or without food), and the specific procedures to follow if a dose is missed.


Q: What steps are generally advised if a known drug interaction occurs with RFD?

Official documents describe the necessary clinical response to interactions. This response can involve required dose modification, close monitoring, or the need to avoid the combination entirely. The healthcare provider uses this official information to guide the treatment plan.


Q: Is RFD a prescription medicine or can I buy it over-the-counter?

The active ingredient in this medication, Pyrantel Pamoate, is generally available over-the-counter (OTC), indicating that a prescription is not required in many regions, including the United States.


Q: Is weight gain or weight loss a potential side effect of RFD?

Official safety documents do not list weight gain or weight loss as a documented adverse reaction of this medication.


Q: What should I do if a side effect of RFD is concerning me?

If any side effect is severe, persistent, or causes concern, official patient safety information advises review by a healthcare professional or seeking immediate medical attention as needed.


Q: What is the typical duration of a course of RFD treatment?

For pinworm infection, the typical course of treatment generally involves two doses of the medication. Official guidelines suggest the second dose be taken approximately two weeks after the first dose.


Q: Is there a generic version of RFD available?

Yes, the active ingredient in this medication is Pyrantel Pamoate, and it is available as a generic medication.


Q: Is it normal to have a dry mouth while using RFD?

Official safety documents and prescribing information do not list dry mouth as a documented adverse reaction of this medication.


Q: What is the risk of RFD being addictive?

This medication is not classified as a controlled substance by regulatory agencies. Furthermore, official documentation does not address a risk of dependence or addiction.


Q: Why is alcohol use often cautioned against when taking medication like RFD?

Official safety information cautions against alcohol use because it carries a risk of increasing the side effect of drowsiness when combined with this medication.


Q: Is RFD a controlled substance?

No. This medication is classified as an Over-The-Counter (OTC) drug and is not listed as a controlled substance by regulatory agencies.


Q: Does RFD have any interaction warnings with over-the-counter pain relievers?

Studies indicate that the medication has minimal systemic absorption, which suggests that clinically significant interactions with common over-the-counter pain relievers or other drugs are generally considered low probability.


Q: Is it necessary to have regular check-ups while on RFD?

Because the drug is used as a short-term treatment course for an acute infection, official regulatory materials do not typically mandate required regular check-ups during the course of the medication itself.


Q: Can RFD interact with herbal teas or natural remedies?

Official drug documents do not specify interactions with particular herbal teas or natural remedies. However, regulatory bodies advise patients to inform a healthcare professional of all products, including supplements, that they are using.


Q: What is the general difference between a contraindication and a warning for RFD?

In official safety documents, a contraindication describes a situation where the drug should absolutely not be used because the risks clearly outweigh the benefits. A warning describes a situation where the drug may be used, but specific precautions or careful monitoring are required.

How should RFD be stored and disposed of?

How to Store and Dispose of Pyrantel Pamoate

Storage and disposal instructions for Pyrantel Pamoate are strictly defined by regulatory labeling to maintain product stability and safety.

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 15°C and 30°C (59°F and 86°F).
Prohibitions Do not freeze. Store away from excessive heat and direct light.
Container Keep the container tightly closed and store the suspension upright.
Child Safety Mandatory instruction is to keep out of the reach of children.

Official Disposal Instructions

Unused or expired medication should be disposed of according to official guidelines. This involves using a local drug take-back program when available. If a take-back program is unavailable, the product may be discarded in the household trash after being mixed with an undesirable substance, placed in a sealed container, and all personal information is removed from the label. The product is not recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of RFD found in:

A-Z Index: